Macitentan

Nov 12, 2019

Actelion Withdraws Regulatory Filings to Extend the Indication of OPSUMIT® (macitentan 10mg) in CTEPH

Oct 21, 2019

New OPSUMIT® (macitentan) Data Show Initial Combination Therapy with Tadalafil Improved Hemodynamic Clinical and Functional Parameters in Patients with Pulmonary Arterial Hypertension

Jun 26, 2019

Tracleer (bosentan; Johnson & Johnson) Drug Overview & Product Profiles 2016-2025

Jun 26, 2019

Opsumit Drug Profile 2016-2025: Opsumit (macitentan; Johnson & Johnson/Nippon Shinyaku) is Set to Become the Market Leader with Forecast Peak Sales of $2.2bn in 2025

Jun 19, 2019

Global Pulmonary Arterial Hypertension Market 2018-2025: Label Expansions Beyond PAH and Evidence Championing Polypharmacy Drive Market Expansion, with Opsumit and Uptravi Leading

Jan 16, 2019

Actelion Receives Complete Response Letter from U.S. FDA for OPSUMIT® (Macitentan) Supplemental New Drug Application

Apr 30, 2018

Actelion Submits Supplemental New Drug Application to US FDA Seeking Approval of OPSUMIT® (macitentan) for the Treatment of Chronic Thromboembolic Pulmonary Hypertension (CTEPH)

Apr 10, 2018

Pulmonary Arterial Hypertension (PAH) Market Size Anticipated to Reach $8.7 Billion by 2025 | Million Insights

Sep 06, 2017

Actelion Receives FDA Approval Of TRACLEER® (bosentan) For Use In Pediatric Patients With Pulmonary Arterial Hypertension